Quality standard
Update information
Update information
February 2016: Statement 6 on the use of valproate in women of childbearing potential has been removed from this quality standard and is replaced by statement 1 in NICE's quality standard on antenatal and postnatal mental health, published in February 2016. This change was made to ensure alignment with that quality standard and reflect more clearly that valproate should not be prescribed to treat mental health problems in women of childbearing potential unless in exceptional circumstances.
Minor changes since publication
August 2024: Changes have been made to the guideline source and recommendation numbers in statement 3 to align with updated NICE guidelines on mental health. The guidelines were simplified by removing recommendations on general principles of care that are covered in other NICE guidelines.
December 2023: Changes have been made to align this quality standard with the updated NICE guideline on cardiovascular disease. Links to source guidance have been updated in the definition of physical health assessment in statement 7.
June 2022: The definition of symptoms of depression in statement 1 and psychological interventions in statement 4 were amended to align with the updated NICE guideline on depression. Minor changes to data sources and references were also made throughout the quality standard.
February 2022: The definition of physical health assessment in statement 7 was amended to be clear that either fasting blood glucose or glycosylated haemoglobin (HbA1c) can be used to assess for diabetes, in line with NICE's 2021 exceptional surveillance of testing for diabetes.